Division of Vascular and Endovascular Surgery, Department of Surgery, Long School of Medicine, University of Texas Health at San Antonio, San Antonio, Tex; South Texas Center for Vascular Care, South Texas Medical Center, San Antonio, Tex.
Division of Vascular and Endovascular Surgery, Department of Surgery, Long School of Medicine, University of Texas Health at San Antonio, San Antonio, Tex; South Texas Center for Vascular Care, South Texas Medical Center, San Antonio, Tex.
J Vasc Surg. 2020 Jul;72(1):233-240.e2. doi: 10.1016/j.jvs.2019.11.035. Epub 2020 Feb 5.
Endovascular tibial interventions for chronic limb-threatening ischemia are frequent, but the implications of early failure (≤30 days) of an isolated tibial intervention are still unclear. The aim of this study was to examine the patient-centered outcomes after early failure of isolated tibial artery intervention.
A database of patients undergoing lower extremity endovascular interventions between 2007 and 2017 was retrospectively queried. Patients with chronic limb-threatening ischemia (Rutherford classes 4, 5, and 6) were selected, and failures within 30 days were identified. Lack of technical success at the time of the procedure was an exclusion. Intention-to-treat analysis by patient was performed. Patient-oriented outcomes of clinical efficacy (absence of recurrent symptoms, maintenance of ambulation, and absence of major amputation), amputation-free survival (survival without major amputation), and freedom from major adverse limb events (MALEs; above-ankle amputation of the index limb or major reintervention [new bypass graft, jump or interposition graft revision]) were evaluated.
There were 1779 patients (58% male; average age, 65 years; 2898 vessels) who underwent tibial intervention for chronic limb-threatening ischemia; 284 procedures (16%) were early failures. In the early failure group, 124 cases (44%) were considered immediate (<24 hours), and 160 cases (56%) failed within the first 30 days after intervention. The two modes of failure were hemodynamic failure (47%) and progression of chronic limb-threatening ischemia (53%). Bypass after early failure was successful in patients with adequate vein, target vessel of ≥3 mm, and good inframalleolar runoff. Progression of symptoms was associated with major amputation in patients with Rutherford class 5 and class 6 disease. Presentation with diabetes and end-stage renal disease were identified as independent clinical predictors for early failure. Lesion calcification, reference vessel diameter <3 mm, lesion length >300 mm, and poor inframalleolar runoff were identified as independent anatomic predictors for early failure and increased MALEs. Early failure was predictive of poor long-term clinical efficacy (11% ± 9% vs 39% ± 8% at 5 years, mean ± standard error of the mean, early vs no early failure; P = .01) and amputation-free survival (16% ± 9% vs 47% ± 9% at 5 years, mean ± standard error of the mean, early vs no early failure; P = .02).
Both clinical and anatomic factors can predict early failure of endovascular therapy for isolated tibial disease. Early failure significantly increases 30-day major amputation and 30-day MALEs and is associated with poor long-term patient-centered outcomes.
慢性肢体威胁性缺血的血管腔内胫骨介入治疗很常见,但孤立性胫骨介入治疗早期失败(≤30 天)的影响仍不清楚。本研究旨在检查孤立性胫骨动脉介入治疗早期失败后的以患者为中心的结果。
回顾性查询了 2007 年至 2017 年下肢血管腔内介入治疗的患者数据库。选择患有慢性肢体威胁性缺血(Rutherford 分级 4、5 和 6)的患者,并确定 30 天内的失败。术中无技术成功是排除标准。通过患者进行意向治疗分析。评估以患者为中心的临床疗效(无复发症状、保持行走能力、无主要截肢)、无截肢生存率(无主要截肢生存率)和无主要肢体不良事件(MALEs;指数肢体的踝上截肢或主要再介入[新旁路移植、跳跃或中间移植修复])。
1779 例患者(58%为男性;平均年龄 65 岁;2898 条血管)接受了慢性肢体威胁性缺血的胫骨介入治疗;284 例(16%)为早期失败。在早期失败组中,124 例(44%)为即刻(<24 小时),160 例(56%)在介入后 30 天内失败。两种失败模式为血液动力学失败(47%)和慢性肢体威胁性缺血进展(53%)。早期失败后旁路手术成功的患者有足够的静脉、≥3mm 的目标血管和良好的踝下流出道。Rutherford 分级 5 级和 6 级疾病患者症状进展与主要截肢有关。患有糖尿病和终末期肾病被确定为早期失败的独立临床预测因素。病变钙化、参考血管直径<3mm、病变长度>300mm 和踝下流出道不良被确定为早期失败和增加 MALEs 的独立解剖学预测因素。早期失败预测长期临床疗效不佳(5 年时 11%±9%与 39%±8%,均数±标准误差,早期与无早期失败;P=0.01)和无截肢生存率(5 年时 16%±9%与 47%±9%,均数±标准误差,早期与无早期失败;P=0.02)。
临床和解剖因素均可预测孤立性胫骨疾病血管腔内治疗的早期失败。早期失败显著增加 30 天内主要截肢和 30 天 MALEs,与长期以患者为中心的结果不佳相关。